Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
暂无分享,去创建一个
R. Motzer | J. Bacik | P. Russo | M. Mazumdar | B. Murphy
[1] L. Schwartz,et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Motzer,et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Motzer,et al. Systemic therapy for renal cell carcinoma. , 2000, The Journal of urology.
[4] M. Mazumdar,et al. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. , 2000, Statistics in medicine.
[5] T. Tammela,et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Figlin. Renal cell carcinoma: management of advanced disease. , 1999, The Journal of urology.
[8] Gareth Griffiths,et al. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.
[9] T. Kuzel,et al. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[11] G. Grateau,et al. Renal-cell carcinoma. , 1997, The New England journal of medicine.
[12] R. Motzer,et al. Renal-cell carcinoma. , 1996, The New England journal of medicine.
[13] E. Lopez Hänninen,et al. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. , 1996, The Journal of urology.
[14] H. Ludwig,et al. Randomised study using IFN-a versus IFN-a plus coumarin and cimetidine for treatment of advanced renal cell cancer , 1995 .
[15] L. Schwartz,et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Sylvester,et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. , 1995, British Journal of Cancer.
[17] S. Fosså,et al. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α , 1994 .
[18] R. Motzer,et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Jones,et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. , 1993, Cancer biotherapy.
[20] R. Motzer,et al. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Philip,et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] S. Fosså,et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] M Schumacher,et al. A bootstrap resampling procedure for model building: application to the Cox regression model. , 1992, Statistics in medicine.
[24] R. Bukowski. Immunotherapy of Renal Cell Carcinoma , 1999, Springer Berlin Heidelberg.
[25] L. Einhorn,et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Trump,et al. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.
[27] J. Droz,et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. , 1988, Seminars in surgical oncology.
[28] C. C. Chen,et al. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.
[29] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[30] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.